Lai, T Y Y <br/><br/>
Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.  [electronic resource] 

 -  Eye (London, England)  Jul 2012 
 - 1004-11 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1476-5454 
<br/><br/><label>Standard No.: </label>10.1038/eye.2012.97  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Bevacizumab<br/>Choroidal Neovascularization--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Intravitreal Injections<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Myopia--complications<br/>Prognosis<br/>Ranibizumab<br/>Refractive Errors--drug therapy<br/>Retrospective Studies<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--physiology